Share
 
Title
Code
Session Type
Channel
Date Time
Chair:

OA04.01 User assessment of a microarray patch for HIV PrEP and as a multipurpose prevention technology for HIV and pregnancy prevention: perspectives from Uganda and South Africa
Ayesha ISMAIL, Genesis Analytics, South Africa
Abstract
OA04.02 High protection against vaginal SHIV infection in macaques by a biodegradable implant releasing tenofovir alafenamide
Ivana MASSUD, Centers for Disease Control and Prevention, United States
Abstract
OA04.03 Distribution of long-acting (LA) cabotegravir (CAB) in plasma, mucosal tissues, and associated fluids after a single ultrasound-guided intramuscular (IM) injection in healthy adult participants
Ethel WELD, John Hopkins University School of Medicine, United States
Abstract
OA04.04 Design and testing of a cabotegravir reservoir implant for HIV prevention
Thomas J HOPE, Feinberg School of Medicine, Northwestern University, United States
Abstract
OA04.05LB Trial design, enrollment status, demographics, and pharmacokinetics (PK) data from a blinded interim analysis from a phase 2a trial of Islatravir once monthly (QM) for HIV pre-exposure prophylaxis (PrEP)
Sharon HILLIER, Magee-Womens Research Institute, United States
Abstract
OA04.06 Live Q&A